<DOC>
	<DOCNO>NCT00921206</DOCNO>
	<brief_summary>The objective ass humoral cellular immune response VAX102 vaccine deliver IM SC prime-boost regimen dose level 1 µg 2 µg healthy adult influenza A virus M2e antigen vaccination .</brief_summary>
	<brief_title>Study Investigate Immune Response Two Doses VAX102 Healthy Adults</brief_title>
	<detailed_description>The primary objective ass humoral cellular immune response VAX102 vaccine deliver IM SC prime-boost regimen dose level 1 µg 2 µg healthy adult influenza A virus M2e antigen vaccination . The magnitude quality M2e-specific B T cell measure . B cell response evaluate pre-dose Days 0 , 28 post-dose Days 7 , 35 , 42 60 . T cell response measure pre-dose Days 0 , 28 post-dose Days 14 , 42 60 . IgG M2e antibody measure Days 0 , 7 , 14 , 28 , 35 . 42 60 . The secondary objective ass safety , reactogenicity , tolerability VAX102 vaccine deliver IM SC dose level 1 µg 2 µg , prime-boost dose regimen , healthy adult 18-49 year age , inclusive .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Male female age 18 49 year inclusive Give write informed consent participate . Healthy , determine medical history , physical examination , vital sign , clinical safety laboratory examination Females willing practice birth control avoid pregnancy study Comprehension study requirement , express availability require study period , ability attend schedule visit . Presence significant acute chronic , uncontrolled medical psychiatric illness ( institution new medical surgical treatment , significant dose alteration uncontrolled symptom drug toxicity within 3 month ) determine medical history and/or physical exam . Cancer , treatment cancer , within 3 year . Persons history cancer diseasefree without treatment 3 year eligible Impaired immune responsiveness ( cause ) , include diabetes mellitus . Documented influenza infection 6 month prior study entry . Presently receive history receive medication treatment affect immune system allergy shot , immune globulin , interferon , immunomodulators , cytotoxic drug drug know frequently associate significant major organ toxicity , systemic corticosteroid ( oral injectable ) past 6 month . Inhaled topical corticosteroid allow . Receipt plan administration nonstudy vaccine within 30 day study Day 42 evaluation . History anaphylactic type reaction inject vaccine . History drug chemical abuse year study . Use new prescription medication start within 7 day study entry . Receipt blood blood product 8 week study entry plan administration study period . Donation blood blood product within 8 week study entry time study . Acute disease within 72 hour prior vaccination , define presence moderate severe illness ( determined investigator medical history physical examination ; example , require absence work ) without fever , fever &gt; 37.9ºC orally . Study vaccine administer person minor illness , diarrhea , mild upper respiratory tract infection without lowgrade febrile illness . Vaccination delay subject recover . Any condition , opinion investigator , might interfere study objective</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>influenza</keyword>
	<keyword>influenza vaccine</keyword>
	<keyword>universal influenza vaccine</keyword>
	<keyword>Matrix 2e protein</keyword>
	<keyword>M2e</keyword>
	<keyword>Immune response</keyword>
</DOC>